| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reiterates | Neutral → Neutral |
| 01/11/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -72.07% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 179.33% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -72.07% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -30.17% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -16.2% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -66.48% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | 39.66% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 318.99% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 67.6% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
What is the target price for TherapeuticsMD (TXMD)?
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on August 17, 2023. The analyst firm set a price target for $5.00 expecting TXMD to rise to within 12 months (a possible 39.66% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $3.58, which is within the analyst's predicted range.